Summary
Treatment with daunorubicin-DNA (DNR-DNA) or adriamycin-DNA (ADM-DNA) has been evaluated in acute lymphoblastic leukemia of childhood (ALL), acute nonlymphoblastic leukemia (ANLL) and bronchogenic carcinoma (BC). The Five-year survival rate in 69 children with ALL was 73.7% when ADM-DNA was introduced in the treatment and 38% with DNR-DNA (P=0.03).
A randomization between free DNR and DNR-DNA for remission induction in 26 patients with ANLL has shown that the drugs were of equivalent effectiveness. The one-year survival rate was 66% for the DNR group and 64% for the DNR-DNA group.
In 59 patients with BC, a randomized trial between ADM-DNA and cyclophosphamide-vinblastine (CTX-VLB) did not show an advantage infavor of one of these treatments. In anaplastic BC (51 patients), there was no difference in survival rate or remission rate between patients treated with ADM or ADM-DNA.
No cardiotoxicity was noted among the patients treated with the complexed drugs. ADM-DNA and DNR-DNA are as effective as the free drugs. Cardiotoxicity appears to be reduced.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benjamin, R. S., Burgess, M. A., Bodey, G. P., McCredie, K. B., Freireich, E. J.: A phase I–II study of adriamycin-DNA complex. Proc. Am. Assoc. Cancer Res. 18, 305 (1977)
Bosly, A., Prignot, J., Ledent, C., Sokal, G., Trouet, A.: Adriamycin and adriamycin-DNA in bronchogenic carcinoma: A randomized study with cyclophosphamide-vinblastine. Eur. J. Cancer 14, 639 (1978)
Cornu, G., Michaux, J. L., Sokal, G., Trouet, A.: Daunorubicin-DNA: Further clinical trials in acute non-lymphoblastic leukemia. Eur. J. Cancer, 10, 695 (1974)
Cutler, S. J., Ederer, F.: Maximum utilization of the life table method in analyzing survival. J. Chronic Dis. 8, 699 (1958)
Hulhoven, R.: Daunorubicin, daunorubicinol and DNA plasma kinetics after i.v. administration of daunorubicin-DNA complex in rabbits. Biomedicine 19, 164 (1978)
Hulhoven, R., Desager, J. P.: Quantitative determination of low levels of daunomycin and daunomycinol in plasma by high-performance liquid chromatography. J. Chromatogr. 125, 369 (1976)
Hulhoven, R., Desager, J. P.: HPLC determination of daunorubicin and daunorubicinol in human plasma. Biomedicine 27, 102 (1977)
Hulhoven, R., Desager, J. P.: Sokal, G., Harvengt, C.: Daunomycin and daunomycinol plasma levels measured by HPLC after perfusions of daunomycin and daunomycin-DNA complex in rabbits: A preliminary report. Arch. Int. Pharmacodyn. Ther. 226, 344 (1977)
Hulhoven, R., Desager, J. P., Sokal, G., Harvengt, C.: Plasma levels and biotransformation of infused daunorubicin and daunorubicin-DNA complex in rabbits: A preliminary report. Eur. J. Cancer 13, 1065 (1977)
Kummen, M., Lie, K. K., Lie, S. O.: A pharmacokinetic evaluation of free and DNA-complexed adriamycin: A preliminary study in children with malignant disease. Acta Pharmacol. Toxicol. (Kbh.) 42, 212 (1978)
Langslet, A., Øye, I., Lie, S. O.: Decreased cardiac toxicity of adriamycin and daunorubicin when bound to DNA. Acta Pharmacol. Toxicol. (Kbh.) 35, 379 (1974)
Lie, S. O., Lie, K. K., Langslet, A.: Experiences with DNA-adriamycin complex in malignant disorders of childhood. In: Adriamycin review. Staquet, M. et al. (eds.), p. 226. Ghent: European Press Medikon 1975
Longueville, J., Maisin, H.: Combined therapy with adriamycin-DNA, vincristine and medroxy-progesterone acetate in metastatic breast cancer. In: Adriamycin review, Staquet, M. et al. (eds.), p. 260. Ghent: European Press Medikon 1975
Michaux, J. L., Cornu, G., Sokal, G., and Trouet, A.: Preliminary clinical trial with the adriamycin-DNA complex in human leukemias and non-Hodgkin lymphomas. In: Adriamycin review. Staquet, M. et al. (eds.), p. 216. Ghent: European Press Medikon 1975
Rozencweig, M., Kenis, Y., Atassi, G., Staquet, M., Duarte-Karim, M.: DNA-adriamycin complex: Preliminary results in animals and man. Cancer Chemother. Rep. 6, 131 (1975)
Sokal, G., Trouet, A., Michaux, J. L., Cornu, G.: DNA-daunorubicin complex: Preliminary trials in human leukemia. Eur. J. Cancer 9, 391 (1973)
Staquet, M., Rozencweig, M., Duarte-Karim, M., Kenis, Y.: Pharmacokinetics of adriamycin and adrimycin-DNA complex in L 1210 mice and men. Eur. J. Cancer 13, 433 (1977)
Trouet, A., Deprez-de Campeneere, D., Duve, C. de: Chemotherapy through lysosomes with a DNA-daunorubicin complex. Nature [New Biol.] 239, 110 (1972)
Trouet, A., Deprez-de Campeneere, D., Smedt-Malengraux, M. de, Atassi, G.: Experimental leukemia chemotherapy with a ‘lysosomotropic’ adriamycin-DNA complex. Eur. J. Cancer 10, 405 (1974)
Author information
Authors and Affiliations
Additional information
Aspirant du Fonds National de la Recherche Scientifique de Belgique
Rights and permissions
About this article
Cite this article
Ferrant, A., Hulhoven, R., Bosly, A. et al. Clinical trials with daunorubincin-DNA and adriamycin-DNA in acute lymphoblastic leukemia of childhood, acute nonlymphoblastic leukemia, and bronchogenic carcinoma. Cancer Chemother. Pharmacol. 2, 67–71 (1979). https://doi.org/10.1007/BF00253108
Issue Date:
DOI: https://doi.org/10.1007/BF00253108